METHODS FOR TREATMENT OF DISEASE, USING BONE MORPHOGENETIC PROTEIN 6 (BMP6) INHIBITORS Russian patent published in 2023 - IPC A61K39/00 A61K39/395 A61P7/06 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely, to a method for the treatment of anemia in a patient, using a BMP6 antagonist, providing for selective administration of therapeutically effective amount of the BMP6 antagonist to the patient based on that a biological sample of the patient is characterized by a ferritin level greater than or equal to 500 ng/ml. In this case, the specified BMP6 antagonist is an antibody to BMP6 or its antigen-binding fragment, containing (i) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 69, 70, and 71, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 79, 80, and 81, respectively; (ii) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 72, 73, and 74, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 82, 83, and 84, respectively; (iii) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 29, 30, and 31, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 39, 40, and 41, respectively; (iv) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 32, 33, and 34, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 42, 43, and 44, respectively; (v) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 49, 50, and 51, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 59, 60, and 61, respectively; (vi) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 52, 53, and 54, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 62, 63, and 64, respectively; (vii) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 9, 10, and 11, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 19, 20, and 21, respectively, or (viii) HCDR1, HCDR2, and HCDR3 sequences under SEQ ID NO: 12, 13, and 14, respectively, and LCDR1, LCDR2, and LCDR3 sequences under SEQ ID NO: 22, 23, and 24, respectively. The group of inventions also relates to a method for selective treatment of anemia in a patient, using a BMP6 antagonist. The group of inventions also relates to a method for prediction of the probability that a patient with anemia will respond to the treatment, using a BMP6 antagonist. The group of inventions also relates to the use of a BMP6 antagonist in the treatment of anemia in a patient.

EFFECT: group of inventions provides the implementation of improved methods for the treatment of anemia.

71 cl, 3 ex, 15 dwg, 8 tbl